$0.740
-0.018 (-2.49%)Al cierre
Comparativa sectorial de BRNS
In the context of the broader market, BRNS competes directly with industry leaders such as BYSI and ABVC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BRNS's gross margin of N/A stands against BYSI's N/A and ABVC's N/A. Such benchmarking helps identify whether Barinthus Biotherapeutics PLC is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Barinthus Biotherapeutics PLC
The company reported total revenue of $14.97 million in Q3 2024 but has faced significant net losses, including -$10.58 million in Q2 2026. The gross margin is currently at 100% for Q3 2024, but this is not sustainable as revenue has dropped to zero in subsequent quarters.
Financials
Artículos relacionados
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
- Bitcoin Bear Market 2026: Why BTC Fell Below $70K and How Investors Can Manage Crypto RiskBitcoin is about 45% below its $126K peak as Fed hikes, 5% yields and ETF outflows bite. See how the 2026 bear market compares and how to manage crypto risk.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.